Medesis Pharma Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Medesis Pharma's earnings have been declining at an average annual rate of -32.6%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 22.8% per year.
Belangrijke informatie
-32.6%
Groei van de winst
-27.4%
Groei van de winst per aandeel
| Biotechs Groei van de industrie | 30.8% |
| Inkomstengroei | 22.8% |
| Rendement op eigen vermogen | n/a |
| Nettomarge | -1,319.7% |
| Laatste winstupdate | 31 Dec 2023 |
Recente prestatie-updates uit het verleden
Geen updates
Recent updates
Opbrengsten en kosten
Hoe Medesis Pharma geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -4 | 1 | 0 |
| 30 Sep 23 | 0 | -3 | 1 | 0 |
| 30 Jun 23 | 0 | -3 | 1 | 0 |
| 31 Mar 23 | 0 | -3 | 1 | 0 |
| 31 Dec 22 | 0 | -3 | 1 | 0 |
| 30 Sep 22 | 0 | -3 | 1 | 0 |
| 30 Jun 22 | 0 | -3 | 1 | 0 |
| 31 Mar 22 | 0 | -3 | 1 | 0 |
| 31 Dec 21 | 0 | -3 | 1 | 0 |
| 30 Sep 21 | 0 | -2 | 1 | 0 |
| 30 Jun 21 | 0 | -2 | 1 | 0 |
| 31 Mar 21 | 0 | -1 | 1 | 0 |
| 31 Dec 20 | 0 | -1 | 0 | 0 |
Kwaliteitswinsten: ALMDP is currently unprofitable.
Groeiende winstmarge: ALMDP is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: Insufficient data to determine if ALMDP's year-on-year earnings growth rate was positive over the past 5 years.
Versnelling van de groei: Unable to compare ALMDP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: ALMDP is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-20.8%).
Rendement op eigen vermogen
Hoge ROE: ALMDP's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.